• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人活化凝血因子通过自身消化和激肽释放酶进行裂解和形成。

The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein.

作者信息

Dunn J T, Silverberg M, Kaplan A P

出版信息

J Biol Chem. 1982 Feb 25;257(4):1779-84.

PMID:6915937
Abstract

We have compared the cleavage of purified human Hageman factor (HF) by an activated form of human Hageman factor (HFa) (autodigestion) and by kallikrein. In each case, an initial cleavage is seen which produces HFa with Mr = 80,000 consisting of a heavy chain of Mr = 52,000 disulfide-linked to a light chain of Mr = 28,000. As autodigestion proceeds, HFa is shown to be further digested to yield a major active product at a molecular weight of 40,000 as well as Hageman factor fragment (HFf), which appear as two closely related molecular species of Mr = 28,000 and 30,000. A minor active product of Mr = 70,000 is also seen. Upon reduction of each of the active forms, a chain with Mr = 28,000 is released which contains the active site. HF digestion by kallikrein results in rapid formation of HFa, followed by HFa digestion to HFf and degradation of the heavy chain region to an inactive fragment at 40,000 daltons, which is then degraded to an end product of Mr = 36,000. Production of the active species with Mr = 40,000 and 70,000 is greatly diminished when kallikrein is the HF activator, and these active forms are shown to be formed primarily by autodigestion. The time course of HFa and HFf formation indicates that the rate of activation of Hageman factor by kallikrein is much faster than the rate of autoactivation; the addition of high molecular weight kininogen increases the rate of HFa and HFf formation as well as the extent of HG digestion. These data indicate that HFa is the active intermediate from which other active species are derived. The patterns of HF and HFa digestion by HFa and kallikrein are distinct; a model for HF digestion is presented.

摘要

我们比较了人活化的哈格曼因子(HFa)(自身消化)和激肽释放酶对纯化的人哈格曼因子(HF)的裂解作用。在每种情况下,都能观察到初始裂解,产生分子量为80,000的HFa,它由一条分子量为52,000的重链通过二硫键连接到一条分子量为28,000的轻链组成。随着自身消化的进行,HFa被进一步消化,产生一种分子量为40,000的主要活性产物以及哈格曼因子片段(HFf),它们表现为两种分子量分别为28,000和30,000的密切相关的分子形式。还观察到一种分子量为70,000的次要活性产物。对每种活性形式进行还原后,会释放出一条分子量为28,000的链,该链含有活性位点。激肽释放酶对HF的消化导致HFa迅速形成,随后HFa被消化为HFf,重链区域降解为一个40,000道尔顿的无活性片段,然后该片段再降解为分子量为36,000的终产物。当激肽释放酶作为HF激活剂时,分子量为40,000和70,000的活性物种的产生会大大减少,并且这些活性形式主要是通过自身消化形成的。HFa和HFf形成的时间进程表明,激肽释放酶激活哈格曼因子的速率比自动激活的速率快得多;添加高分子量激肽原会增加HFa和HFf形成的速率以及HF消化的程度。这些数据表明HFa是衍生出其他活性物种的活性中间体。HFa和激肽释放酶对HF和HFa的消化模式不同;本文提出了一个HF消化的模型。

相似文献

1
The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein.人活化凝血因子通过自身消化和激肽释放酶进行裂解和形成。
J Biol Chem. 1982 Feb 25;257(4):1779-84.
2
Formation and structure of human Hageman factor fragments.人凝血因子片段的形成与结构
J Clin Invest. 1982 Sep;70(3):627-31. doi: 10.1172/jci110656.
3
Hageman factor-dependent pathways: mechanism of initiation and bradykinin formation.哈格曼因子依赖性途径:启动机制与缓激肽形成
Fed Proc. 1983 Nov;42(14):3123-7.
4
Kinin release from high molecular weight kininogen by the action of Hageman factor in the absence of kallikrein.在没有激肽释放酶的情况下,通过Hageman因子的作用从高分子量激肽原释放激肽。
J Biol Chem. 1983 Jul 25;258(14):8963-70.
5
Autoactivation of human Hageman factor. Demonstration utilizing a synthetic substrate.人凝血因子Ⅻ的自动激活。利用合成底物的证明。
J Biol Chem. 1980 Aug 10;255(15):7281-6.
6
Hageman factor substrates. Human plasma prekallikrein: mechanism of activation by Hageman factor and participation in hageman factor-dependent fibrinolysis.哈格曼因子底物。人血浆前激肽释放酶:哈格曼因子的激活机制及参与哈格曼因子依赖性纤维蛋白溶解作用。
J Biol Chem. 1977 Sep 10;252(17):6097-104.
7
Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma.血浆接触激活过程中产生的两种活化哈格曼因子形式的表面活性和液相活性。
J Exp Med. 1978 Mar 1;147(3):719-29. doi: 10.1084/jem.147.3.719.
8
Activation of human Hageman factor by a leukocytic protease.一种白细胞蛋白酶激活人哈格曼因子。
Adv Exp Med Biol. 1979;120B:139-51.
9
Mechanisms for Hageman factor activation and role of HMW kininogen as a coagulation cofactor.哈格曼因子激活机制及高分子量激肽原作为凝血辅因子的作用。
Ann N Y Acad Sci. 1981;370:253-60. doi: 10.1111/j.1749-6632.1981.tb29738.x.
10
Studies on prekallikrein of bovine plasma. II. Activation of prekallikrein with proteinases and properties of kallikrein activated by bovine Hageman factor.牛血浆前激肽释放酶的研究。II. 用蛋白酶激活前激肽释放酶以及牛哈格曼因子激活的激肽释放酶的特性
J Biochem. 1980 Jan;87(1):23-34. doi: 10.1093/oxfordjournals.jbchem.a132730.

引用本文的文献

1
Plasma kallikrein supports FXII-independent thrombin generation in mouse whole blood.血浆激肽释放酶支持小鼠全血中 FXII 非依赖性凝血酶生成。
Blood Adv. 2024 Jun 25;8(12):3045-3057. doi: 10.1182/bloodadvances.2024012613.
2
Rediscovery of a forgotten disease: Hereditary Angioedema.一种被遗忘疾病的重新发现:遗传性血管性水肿。
Balkan Med J. 2021 Mar;38(2):68-72. doi: 10.5152/balkanmedj.2021.20030.
3
Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent.补体、激肽与遗传性血管性水肿:C1 抑制剂缺乏时血浆不稳定的机制
Clin Rev Allergy Immunol. 2016 Oct;51(2):207-15. doi: 10.1007/s12016-016-8555-6.
4
A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation.因子 XII 缺乏症和前激肽释放酶缺乏症对血栓形成影响的比较。
Thromb Res. 2016 Apr;140:118-124. doi: 10.1016/j.thromres.2016.02.020. Epub 2016 Feb 18.
5
Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels.C1抑制剂水平正常的遗传性血管性水肿患者血浆中纤溶酶原激活物抑制剂2缺乏
J Allergy Clin Immunol. 2016 Jun;137(6):1822-1829.e1. doi: 10.1016/j.jaci.2015.07.041. Epub 2015 Sep 26.
6
Amidolytic, procoagulant, and activation-suppressing proteins produced by contact activation of blood factor XII in buffer solution.在缓冲液中,通过血液因子 XII 的接触激活产生的具有 amidolytic、促凝和抑制激活作用的蛋白质。
Biomaterials. 2011 Dec;32(36):9747-57. doi: 10.1016/j.biomaterials.2011.09.020. Epub 2011 Sep 28.
7
The many faces of the contact pathway and their role in thrombosis.接触途径的多面性及其在血栓形成中的作用。
J Thromb Thrombolysis. 2011 Jul;32(1):9-20. doi: 10.1007/s11239-011-0578-5.
8
Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis.因子 XII:它对我们理解止血和血栓形成的生理学和病理生理学有何贡献。
Thromb Res. 2010 Mar;125(3):210-5. doi: 10.1016/j.thromres.2009.11.028.
9
Surface-energy dependent contact activation of blood factor XII.表面能依赖性接触激活血液因子 XII。
Biomaterials. 2010 Feb;31(6):1068-79. doi: 10.1016/j.biomaterials.2009.10.039. Epub 2009 Nov 4.
10
Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis.Ir-CPI是一种来自蓖麻硬蜱的凝血接触相抑制剂,它能抑制血栓形成而不损害止血功能。
J Exp Med. 2009 Oct 26;206(11):2381-95. doi: 10.1084/jem.20091007. Epub 2009 Oct 5.